RGNX Snapshot
REGENXBIO Inc., a clinical-stage biotechnology company, offers candidate gene therapy products to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies intended to affect disease. The company is headquartered in Rockville, Maryland.
Market Capitalization$866,129,000
Price to Sales1.83
Earnings per Share$2.2900
PE Ratio8.77
Most Recent Close$19.5600
52 Week High$46.46
52 Week Low$18.69
50-Day Moving Average$28.07
200-Day Moving Average$31.34
All data are from Alpha Vantage as of today. For more infomation on RGNX see Stock Dividend, Valuation, Price and Financial Data for Investors